Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Home CompaniesBioNTech SE

BioNTech SE

PortfolioPortfolio WatchlistWatchlist
Company price
None GBX 0.00(0%)
Last update at 2026-10-28T03:28:18.621358Z
Market Cap
0.00M
P/E
0.03

Momentum Score

…

BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast cancer, and Trastuzumab pamirtecan for metastatic breast cancer and epirubicin and cyclophosphamide; and drugs under Phase 2/3 clinical trial, such as BNT113 for human papillomavirus and head and neck squamous cell carcinoma, as well as Pumitamig for metastatic colorectal and non-small cell lung cancer. In addition, the company engages in the development of oncology drugs under Phase II clinical trial comprising BNT116 for advance non-small cell lung cancer, BNT326/YL202 for multiple solid tumors and advanced/metastatic breast cancer, Autogene cevumeran for advance colorectal cancer, and Gotistobart for platinum-resistant ovarian cancer, as well as Pumitamig for glioblastoma, hepatocellular carcinoma, malignant pleural mesothelioma, neuroendocrine neoplasms, and metastatic pancreatic ductal adenocarcinoma. Further, it develops BNT166 which is Phase II clinical trial for mpox virus; and infectious diseases drugs under Phase 1/2 clinical trial, which include BNT162 + BNT161 for SARS-CoV-2 and influenza, BNT164 for tuberculosis, BNT165 for malaria, and BNT166 for mpox. The company was incorporated in 2008 and is headquartered in Mainz, Germany.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
79.51
Low
125.70
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
86.50
Dividend Yield
-
Revenue TTM
2869.90M
Revenue Per Share
11.87
Gross Profit TTM
2258.60M
Debt / Equity
0.17
ROE
-5.88%
Net Debt
-
ROCE
695.74%
Diluted EPS TTM
52.02

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax - - -145.80M -179.44M -47.66M
Minority interest - - - - 0.85M
Net income - - 15.20M -179.06M -48.02M
Selling general administrative - - 103.46M 44.45M 27.07M
Gross profit - - 422.99M 91.23M 113.89M
Ebit 11915.30M 14698.10M -325.80M -181.50M -53.90M
Operating income - - -82.42M -181.52M -53.85M
Other operating expenses 319.10M 81.70M 9.10M 2.50M 5.15M
Interest expense - 0.00M 0.00M 0.00M 0.00M
Tax provision - - -161.00M -0.27M 0.60M
Interest income - - 60.34M 2.40M 6.24M
Income tax expense - 4753.90M -161.00M -0.20M 0.60M
Total revenue - - 482.32M 108.59M 127.58M
Cost of revenue - - 59.33M 17.36M 13.69M
Net income applicable to common shares - 10292.50M 15.20M -179.10M -48.02M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets - - 2318.62M 797.65M 652.99M
Intangible assets - - 109.79M 86.46M 87.51M
Other current assets - 113.40M 89.00M 7.04M 2.48M
Total liab - - 946.77M 304.15M 386.83M
Total stockholder equity - - 1371.85M 493.49M 266.15M
Deferred long term liab - 13.60M - - -
Other current liab - 3191.70M 494.60M 105.63M 77.03M
Common stock - 246.30M 246.30M 232.30M 193.30M
Retained earnings - 9882.90M -409.60M -424.83M -245.77M
Other liab - 283.90M 109.80M 97.11M 205.65M
Good will - - 53.70M 2.98M 0.53M
Other assets 249.20M 22.20M 168.20M 2.40M 1.50M
Cash - - 1210.21M 519.15M 411.50M
Total current liabilities - 3481.60M 606.00M 138.14M 126.12M
Short long term debt total - - 231.05M 68.90M 5.60M
Other stockholder equity - 1768.30M 1539.90M 691.54M 318.63M
Property plant equipment - 520.40M 326.00M 148.06M 115.97M
Total current assets - 15072.30M 1666.90M 560.15M 448.96M
Net tangible assets - 11699.10M 1214.30M 406.46M 179.61M
Short term investments - - 137.23M 1.68M 0.34M
Net receivables - 12382.10M 166.40M 20.20M 28.71M
Long term debt - - 153.02M 14.78M 5.60M
Inventory - 502.50M 64.10M 12.07M 5.94M
Accounts payable - 160.00M 102.30M 20.50M 41.72M
Treasury stock - - -4.79M -5.53M -
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Investments - - - -394.70M -394.70M
Change to liabilities - - - 1516.10M 204.60M
Total cashflows from investing activities - - - -566.10M -144.80M
Net borrowings - - - -66.70M 141.70M
Total cash from financing activities - - - 94.20M 894.70M
Net income -665.30M 930.30M 9434.40M 10292.50M 15.20M
Change in cash - - - 482.50M 691.10M
Total cash from operating activities - - - 889.70M -13.50M
Depreciation - - - 75.20M 38.70M
Other cashflows from investing activities - - - - -59.40M
Change to inventory - - - -438.40M -49.80M
Change to account receivables - - - -11808.10M -247.90M
Sale purchase of stock - - - - 753.01M
Other cashflows from financing activities - - - -2.70M -2.70M
Change to netincome - - - 1252.40M 25.70M
Capital expenditures 0.00M 0.00M 0.00M 127.50M 66.00M
Change in working capital - - - - -94.90M

Peer Comparison*

Sector: Industry:

Stock Name
Change
(GBX)
Price
(GBX)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
0R15
SoftBank Group Corp.		 248.00
5.84%		 4494.00 - - - -
0R1E
Nintendo Co. Ltd.		 -115.00
1.34%		 8476.00 - - - -
0LC3
Synchrony Financial		 2.34
3.20%		 75.60 0.09 - 4.97 -
0HQP
CBRE Group Inc. Cl A		 0.15
0.12%		 122.47 0.25 - 1.18 -

Profile*

BioNTech SE

BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast cancer, and Trastuzumab pamirtecan for metastatic breast cancer and epirubicin and cyclophosphamide; and drugs under Phase 2/3 clinical trial, such as BNT113 for human papillomavirus and head and neck squamous cell carcinoma, as well as Pumitamig for metastatic colorectal and non-small cell lung cancer. In addition, the company engages in the development of oncology drugs under Phase II clinical trial comprising BNT116 for advance non-small cell lung cancer, BNT326/YL202 for multiple solid tumors and advanced/metastatic breast cancer, Autogene cevumeran for advance colorectal cancer, and Gotistobart for platinum-resistant ovarian cancer, as well as Pumitamig for glioblastoma, hepatocellular carcinoma, malignant pleural mesothelioma, neuroendocrine neoplasms, and metastatic pancreatic ductal adenocarcinoma. Further, it develops BNT166 which is Phase II clinical trial for mpox virus; and infectious diseases drugs under Phase 1/2 clinical trial, which include BNT162 + BNT161 for SARS-CoV-2 and influenza, BNT164 for tuberculosis, BNT165 for malaria, and BNT166 for mpox. The company was incorporated in 2008 and is headquartered in Mainz, Germany.

An der Goldgrube 12, Mainz, Germany, 55131

49 6131 9084

https://www.biontech.de

7807

Name Title Year Born
Prof. Ugur Sahin M.D. Co-Founder, CEO & Chair of the Management Board 1965
Dr. Ozlem Tureci M.D. Co-Founder, Chief Medical Officer & Member of Management Board 1967
Prof. Christoph Hubert Huber M.D., Ph.D. Co-Founder & Member of Supervisory Board 1944
Mr. Jens H. Holstein CFO & Member of Management Board 1963
Dr. Sierk Poetting Ph.D. MD, COO & Member of Management Board 1973
Mr. Ryan Richardson Chief Strategy Officer, MD & Member of Management Board 1979
Mr. Sean Marett Chief Bus. Officer, Chief Commercial Officer & Member of Management Board 1965
Sylke Maas Ph.D. VP of Investor Relations and Bus. Strategy NA
Dr. James Timothy Patrick Ryan Ph.D. Sr. VP & Gen. Counsel NA
Michael Boehler MD & Head of Global External Communications NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

DAR
GBX 8.30
+23.42%
VTY
GBX 276.20
+8.23%
GTCO
GBX 0.09
+6.98%
GLV
GBX 2.34
+6.36%
BUR
GBX 249.20
+5.95%
TMI
GBX 0.72
-6.49%
HSBA
GBX 1291.40
-5.42%
RKT
GBX 5218.00
-4.85%
TGA
GBX 643.00
-4.03%
RKH
GBX 61.70
-3.89%

Equity Sectors*

  • Basic Materials

    -1.70%

  • Communication Services

    +0.33%

  • Consumer Cyclical

    +0.45%

  • Consumer Defensive

    -0.56%

  • Energy

    -0.25%

  • Financial Services

    +0.49%

  • Healthcare

    +0.20%

  • Industrials

    +0.74%

  • Real Estate

    +1.71%

  • Technology

    -2.81%

  • Utilities

    +0.28%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Cookies on this website

We use some essential cookies to make this site work. We also set analytics and marketing cookies, described below, to understand how you use the site and to measure our advertising. For more detailed information, see our Cookie Policy, Privacy Policy and Terms and Conditions.

Essential cookies

These cookies are necessary for core functionality, such as security, your shopping cart, remembering your cookie choice, and your progress through a report or free-trial request you started. They always need to be on.

Analytics cookies

We use analytics cookies to understand how visitors use the site — the pages visited, time spent, and where visitors came from.

Marketing cookies

These help us measure how effective our advertising is, such as recording actions you take after clicking one of our ads. If you don't enable this, you may still see our ads, but they won't be measured this way.

Support

Hi! How can we help you today?

Loading…